Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional recovery after eight months

M Capelli and P Gatti

Department of Otolaryngology, Columbus Clinic Center, Milan, Italy

Author for correspondence:
Dr Marco Capelli, Department of Otolaryngology, Columbus Clinic Center, Via Michelangelo Buonarroti, 48, 20145 Milan, Italy
E-mail: info@otorinocremona.it

Dr M Capelli takes responsibility for the integrity of the content of the paper

Accepted: 20 January 2021

Key words:
Anosmia; SARS-CoV; Smell; Olfaction; Epidemics; Outbreaks

Abstract

Background. Severe acute respiratory syndrome coronavirus-2 is a formidable virus, responsible for coronavirus disease 2019 and endowed with marked neurotropism. The damage it causes to the nervous system is manifold. The main neurological manifestation is anosmia. Olfactory damage is often transient, but there are no data reflecting an observational period of several months.

Objective. This study evaluated the trend of anosmia in patients affected by coronavirus disease 2019 in the eight months following diagnosis.

Methods. Fifty-five subjects who presented with symptoms suggestive of coronavirus disease 2019 and who developed anosmia, between the end of February and the beginning of March 2020, were investigated. The patients were interviewed after eight months to determine functional recovery and assess the degree of recovery.

Results. Ninety-one per cent of the population reported olfactory recovery and, of these, 53 per cent had total recovery after eight months. Females and younger age groups seem slightly advantaged in functional recovery. The elderly population appears to have excellent prospects for full functional recovery.
Conclusion. Anosmia represents a frequent neurological manifestation during coronavirus disease 2019. Fortunately, it is transient in most cases, and only a small percentage of patients affected by it report long-term functional deficits.

Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection represents a worldwide emergency given its exponential spread and associated clinical picture (coronavirus disease 2019 (Covid-19)), which is sometimes very severe, and can lead to respiratory failure and death.

On 21 February 2020, the first case of Covid-19 in Italy was diagnosed at the Codogno Hospital. The causative agent is a new coronavirus defined by the International Committee on Taxonomy of Viruses as SARS-CoV-2.

Coronavirus disease 2019 is a new pathological entity that is still not fully understood; it is characterised by several clinical manifestations. Initially, low-grade fever, asthenia, malaise and cough were considered the typical symptoms of the disease. Later gastroenterological symptoms such as diarrhoea were also considered pathognomonic. Several studies have since demonstrated the association between anosmia and SARS-CoV-2 infection.

We observed an exponential increase of patients with olfactory deficit in the territory of southern Lombardy (the site of the first European Covid-19 outbreak) between the end of February and the beginning of March, and we consequently described the first series in Europe of patients affected by anosmia during SARS-CoV-2 infection. Klapfenstein et al. conducted a study on 114 patients affected by Covid-19, in which 54 (47 per cent) were affected by anosmia. They found that symptom onset occurred about 4 days after infection, with an average duration of about 9 days. Ninety-eight per cent of patients had recovered function within 28 days. Moein et al. published a case–control study in which the olfactometric test results of Covid-19 patients and healthy patients were compared, with evident olfactory deficits in the former group.

The continuous succession of studies demonstrating the relationship between anosmia and SARS-CoV-2 infection has led the World Health Organization (WHO) to consider anosmia as a specific symptom of Covid-19. Once this association was clarified, researchers’ efforts were directed towards understanding the pathogenetic mechanisms of anosmia, as described in a paper by Bilinska and Butowt.

The long-term evolution of neurological symptoms – and of anosmia in particular – associated with Covid-19 remains to be understood. Several studies in the literature illustrate the trend of anosmia in the weeks following the infection, but very few present long-term follow-up data. We collected data for the
population of the first European outbreak and monitored the trend of olfactory dysfunction, with an observational period of eight months.

**Materials and methods**

We conducted a retrospective study on patients suffering from anosmia in the territory corresponding to the first epidemic outbreak in Europe in the months following the first European case of Covid-19 (21 February 2020).

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines on human experimentation, and with the Helsinki Declaration of 1975, as revised in 2008.

The criteria for inclusion in the study were: adult patients aged over 18 years; symptoms suggestive of Covid-19 (fever, asthenia, cough, sore throat and myalgia); resident in the territory of the first European outbreak of Covid-19 (i.e. in the city of Codogno and neighbouring regions); and patients with good knowledge of the Italian language, able to correctly understand the doctor's instructions and requests.

Patients with minor symptoms, those suffering from previous disturbances of smell, acute bacterial rhinosinusitis, acute allergic rhinosinusitis, nasal polyposis, granulomatous sinonasal pathologies, sinonasal neoplasm, neurodegenerative diseases or other pathologies of the central and peripheral nervous system, and patients treated with high-flow oxygen through non-invasive ventilation (continuous positive airway pressure) were excluded from the study.

We analysed the anamnestic data from our database and collected the details for 55 patients suffering from anosmia between February and March 2020. There were 20 males (36 per cent) and 35 females (64 per cent), aged 18–75 years (average age of 44 years).

The patients were all contacted by telephone and interviewed about the recovery (or not) of their olfactory function eight months later. When interpreting the results, we considered some variables such as gender and age, and tried to understand their possible role in olfactory functional recovery.

This novel study aimed to observe the trend and evolution of anosmia in subjects with Covid-19 symptoms over an observational period of eight months, without considering the therapeutic variables.

**Statistical analysis**
Statistical analysis was performed using the chi-square test with a significance level of 5 per cent. The analysis aimed to verify the recovery of olfactory function in a population affected by anosmia, eight months after the onset of symptoms. We also used the chi-square test to verify the relationship between male and female gender and olfactory recovery, and to verify the influence of the subject's age in functional recovery.

**Results**

The results observed in this study are summarised in Table 1.

The first aspect we wanted to investigate was the recovery (total or partial) of olfactory function, compared to the initial condition of anosmia, in the studied population. We found that 50 patients showed some form of olfactory recovery from the initial condition of anosmia after eight months. This means that a patient with post-infectious anosmia had a 91 per cent empirical probability of olfactory recovery. Of these patients, 29 achieved total recovery while 21 had partial recovery (i.e. with an empirical probability of recovery of 53 per cent and 38 per cent, respectively). The empirical probability calculated for the five patients with persistence of anosmia after eight months is 9 per cent.

We then tried to understand the role of some variables such as age and gender on olfactory recovery in our population. We initially considered the 91 per cent of the population that showed some form of olfactory recovery. We found a statistically significant difference in functional recovery associated with gender. Specifically, females recovered more olfactory functionality than males, as evidenced by the chi-square test results (Table 2).

We then divided our sample into four age groups (less than 35 years, 35–50 years, 50–65 years and more than 65 years). In this instance, we observed the greatest recovery in the two younger groups (patients aged less than 35 years and 35–50 years). This finding was statistically significant, as demonstrated with the chi-square test (Table 3).

Finally, we studied the 53 per cent of the population that reported total olfactory functional recovery. In these patients, we observed that males had greater recovery (Table 4), with better recovery in the youngest (less than 35 years) and the oldest (more than 65 years) groups (Table 5). Again, the statistical analysis was performed with a chi-square test.
Discussion

The first European cases series of patients affected by anosmia in Covid-19 dates back to the last week of February. Since then, many studies have confirmed the hypothesis that anosmia is a characteristic symptom of Covid-19. Anosmia was subsequently confirmed by WHO to be a distinctive symptom of Covid-19 and an early indicator of the disease. On the basis of this belief, the Italian researchers Mazzatenta and colleagues have experimented with a rapid test for the recognition of olfactory disturbances in patients with suspected SARS-CoV-2 infection. We now know that anosmia is the most frequent manifestation among those with SARS-CoV-2 in the nervous system.

In a review published in May 2020, Ahmed et al. precisely described the neurological manifestations resulting from infection with SARS-CoV-2 and the possible routes of access by the virus to the central nervous system. It is thought that the binding between angiotensin-converting enzyme-2 (ACE2) receptors and SARS-CoV-2 protein S may be the basis of neuronal and vascular damage within the central nervous system. Mao et al. believe that the damage to olfactory neurons (rich in ACE2 receptors) can be induced by the direct entry of the virus through the cribriform plate.

Hopkins et al. surveyed 382 patients affected by olfactory alteration during the Covid-19 pandemic. The work was important in demonstrating the frequent and rapid recovery of olfactory function. Of the patients studied, 86.4 per cent presented with complete anosmia and 11.5 per cent had severe olfactory loss. After only 7 days, 80.1 per cent showed an improvement in symptoms and, of these, 11.5 per cent reported complete recovery. The follow-up period, however, was very short and does not allow us to understand the long-term trend of the symptoms.

The need for long-term observational results is supported by Otte et al., who acknowledge that there is currently no literary work evaluating the trend of post-infectious olfactory disorder from SARS-CoV-2 several months after onset. In fact, the same authors followed a series of 80 patients for only two months.

Our study aimed, albeit with some limitations, to examine the population relating to the first European outbreak of coronavirus with a follow up of eight months. The main limitations of our study are: the lack of objective instrumental evidence regarding the loss or recovery of olfactory function; and the fact that not all anosmic patients at the time of infection were able to undergo serological tests or identification of viral RNA by polymerase chain reaction, on samples taken using nasal swabs. However, the patients studied presented a clinical picture suggestive of Covid-19 and were resident in an area with a high rate of infection.
Given the limited availability of diagnostic tests in relation to the high number of affected subjects, between the end of February and the beginning of March 2020, in the territory where the study was carried out, many patients were not given the opportunity to undergo diagnostic tests and to have certain confirmation of the very probable SARS-CoV-2 infection. Only 40 per cent of the patients studied had the opportunity to undergo serological or polymerase chain reaction testing, and in all cases SARS-CoV-2 positivity was confirmed.

Regarding this last aspect, we must remember that the group of patients studied represents a sample of the first severely affected population in Europe (first European epidemic outbreak), and in it the percentage of individuals affected by Covid-19 was very high. We believe that although serological positivity to SARS-CoV-2 had not been confirmed in all anosmic patients, it is highly probable that the onset of olfactory alteration in the epidemic peak phase and SARS-CoV-2 infection are closely related, and we therefore believe the population sample to be congruent with the purposes of the study.

On 21 February 2020, the first Italian case of Covid-19 was diagnosed at the Codogno Hospital. The territory of Lower Lodigiano (around Codogno) has been the scene of numerous cases of infection, and can thus be considered epidemiologically to be the site of the first European outbreak. In this area, between the end of February and the beginning of March 2020, we observed a considerable number of cases of anosmia (55 patients), and we monitored the trend of the olfactory deficit in the eight months following the onset of the infection. Table 1 shows the data for the patients followed.

The results obtained appear comforting, as we observed that 38 per cent of the population showed partial olfactory recovery and 53 per cent reported total recovery eight months after onset. Overall, 91 per cent of the population showed an improvement in olfactory function eight months after onset of the olfactory deficit. Our results show higher recovery percentages at eight months than Hopkins et al. who evaluated patients over a few weeks of follow up (80.1 per cent). This would suggest possible functional recovery even after a long time, and at least a stability of functional recovery if it occurs early.

We also observed that, after eight months, the probabilities of functional recovery differed only minimally in relation to gender, with females slightly more advantaged in terms of the possibility of recovery in general, but with males more advantaged in terms of total recovery.

Furthermore, our data suggest that the population aged under 50 years has the greatest probability of olfactory recovery. We observed total or partial recovery in 100 per cent of patients aged 35–50 years, and in 95 per cent of patients aged under 35 years. The percentages of olfactory recovery decrease with increasing age. However, interestingly, the highest percentage of total olfactory recovery was recorded in the oldest group, aged over 65 years (71.5 per cent).
Therefore, the youngest group (aged less than 35 years) and the oldest group (aged over 65 years) had an advantage in terms of their capacity for complete olfactory recovery. This datum, confirmed by statistical significance with the chi-square test, is not easy to interpret. We could hypothesise that, in the younger population, greater neuroplasticity favours better functional recovery; however, it is currently difficult to explain the good functional recovery achieved by the older population. We could postulate that, in older subjects, factors such as a less hectic lifestyle, a greater habit of observing prescribed medical therapies, the lack of intense professional activity (typical of middle-aged subjects), and consequently a lower exposure to psychophysical stress, may contribute to the higher probability of complete olfactory functional recovery.

An interesting finding worthy of future studies is the partial but subjectively satisfactory olfactory recovery, of cacosmia or recurrent parosmia, reported by 14 patients (equal to 25.4 per cent of the population studied). Although the mechanisms are not completely clear at present, we believe this finding may somehow be attributable to the neurotropism of SARS-CoV-2 and to its potential neurodegenerative activity. This belief was instigated by the findings of a study by Bilinska and Butowt, which describes the alleged pathogenetic mechanism through which SARS-CoV-2 would induce damage to the olfactory structures and the consequent anosmia, based on results obtained from patients and animal models.

This hypothesis is in turn aligned with the considerations of Mao et al., who were among the first to describe the various neurological manifestations resulting from SARS-CoV-2 infection. These authors describe the manifestations related to central nervous system involvement (such as dizziness, ataxia, headache and convulsions), manifestations of the peripheral nervous system involvement (such as anosmia) and neuromuscular manifestations.

It seems that SARS-CoV-2 can reach and affect nervous system structures through different pathways: by a hematogenous route, by a direct sensorineural route and by a retrograde neuronal route. Once the infection comes into contact with these, it binds to their ACE2 receptors (present on the cell surface), and then penetrates into nerve cells and causes neuronal damage. Yan et al. also underline the neuroinvasive potential of SARS-CoV-2, as described in myocardial complications by Zheng et al.

Based on the numerous studies in the literature, it is now considered certain that SARS-CoV-2 causes neurological damage as well as there being tropism towards the neuro-olfactory epithelium. We are studying and understanding more and more the pathogenetic mechanisms that determine this neuroinvasiveness. Little is known about the future development of post-infectious neurological deficits. With reference to the loss of the olfactory function, we believe that further studies will improve our knowledge regarding its recovery.

- Anosmia is a frequent symptom in coronavirus disease 2019
- Patients suffering from anosmia complain of significant quality of life impairment
- Recovery of functional deficit is common
• There are no data available on the long-term deficit trend
• This study is the first to evaluate the course of anosmia after eight months
• The relationships between olfactory recovery and age and gender were investigated in a sample of the first European outbreak population

Conclusion

The SARS-CoV-2 infection can manifest itself through various clinical pictures. In most cases, it begins asymptptomatically or mildly symptomatic. Loss of olfactory function is a typical and frequent manifestation of Covid-19. However, we still know little about this pathology and the probabilities of functional recovery of the sensorineural deficits associated with it.

Hence, we performed a study on the anosmic population of the first epidemic outbreak in Europe, with the aim of understanding the probabilities of post-infectious functional recovery. We observed that in most cases that the olfactory deficit is followed by total or partial recovery of function eight months later. The findings of this study, conducted on a small population, will have to be confirmed by others that incorporate larger numbers, but it represents one of the first studies characterised by a long follow up.

Acknowledgements. The authors would like also to thank Ornella Ponzoni for her valuable support and Dr Matilde Grecchi for her contribution to the statistical analysis and data presentation.

Competing interests. None declared

References

1 Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71–6
2 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44
3 Capelli M, Gatti P. Anosmia and COVID-19 in south Lombardy: description of the first cases series in Europe. B-ENT 2020;16:86–90
4 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2020
5 Van der Poel N, Mansbach AL, Loundon N, Russell J, Vanderveken OM, Boudewyns A. Challenges in pediatric otolaryngology in the COVID-19 pandemic: insights from current protocols and management strategies. *B-ENT* 2020;**16**:59–62

6 Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V *et al*. Features of anosmia in COVID-19. *Med Mal Infect* 2020;**50**:436–9

7 Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol* 2020;**10**:944–55

8 Otte MS, Eckel HNC, Poluschkin L, Klussmann JP, Luers JC. Olfactory dysfunction in patients after recovering from COVID-19. *Acta Otolaryngol* 2020;**140**:1032–5

9 Vroegop AV, Eeckels AS, Van Rompaey V, Van den Abeele D, Schiappoli M, Alobid I *et al*. COVID-19 and olfactory dysfunction - an ENT perspective to the current COVID-19 pandemic. *B-ENT* 2020;**16**:81–5

10 Lechien JR, Chiesta-Estomba CM, De Siai DR, Horoi M, Le Bon SD, Rodriguez A *et al*. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicentre European study. *Eur Arch Otorhinolaryngol* 2020;**277**:2251–61

11 Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy Rhinol* 2020;**10**:806–13

12 Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A *et al*. Objective evaluation of anosmia and ageusia in COVID-19 patients: a single-center experience on 72 cases. *Head Neck* 2020;**42**:1252–8

13 Bilinska K, Butowt R. Anosmia in COVID-19: a bumpy road to establishing a cellular mechanism. *ACS Chem Neurosci* 2020;**11**:2152–5

14 Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. *Rhinology* 2020;**58**:295–8

15 Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? *Rhinology* 2020;**58**:299–301

16 Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study. *J Otolaryngol Head Neck Surg* 2020;**49**:26

17 Vaira L, Hopkins C, Sandison A, Manca A, Machouchas N, Turilli D *et al*. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. *J Laryngol Otol* 2020;**134**:1123–7

18 Mazzatenta A, Neri G, D’Ardes D, De Luca C, Marinari S, Porreca E *et al*. Smell and taste in severe CoViD-19: self-reported vs. testing. *Front Med (Lausanne)* 2020;**7**:589409

19 Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM *et al*. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. *Front Neurol* 2020;**11**:518

20 Mao L, Jin H, Wang M, Hu Y, Chen S, He Q *et al*. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol* 2020;**77**:683–90

21 Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: a review based on up-to-date knowledge. *Am J Otolaryngol* 2020;**41**:102581
22 Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. *Am J Respir Crit Care Med* 2020;202:756–9

23 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020;17:259–60

24 Freni F, Meduri A, Gazia F, Nicastro V, Galletti C, Aragona P et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): a possible neuroinvasive action of SARS-CoV-2. *Am J Otolaryngol* 2020;41:102612

25 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. *J Med Virol* 2020;92:55–5

26 Avci H, Karabulut B, Farasoglu A, Boldaz E, Evman M. Relationship between anosmia and hospitalisation in patients with coronavirus disease 2019: an otolaryngological perspective. *J Laryngol Otol* 2020;134:710–16

**Table 1.** Descriptive data for the population after eight months’ follow-up

| Parameter          | Complete recovery | Partial recovery | Absent recovery | Total |
|--------------------|-------------------|------------------|-----------------|-------|
| Gender             |                   |                  |                 |       |
| – Male             | 11 (55)           | 7 (35)           | 2 (10)          | 20    |
| – Female           | 18 (51)           | 14 (40)          | 3 (9)           | 35    |
| Age range          |                   |                  |                 |       |
| – 18–35 years      | 13 (62)           | 7 (33)           | 1 (5)           | 21    |
| – 35–50 years      | 5 (42)            | 7 (58)           | 0 (0)           | 12    |
| – 50–65 years      | 6 (40)            | 7 (47)           | 1 (13)          | 15    |
| – 65–75 years      | 5 (71.5)          | 0 (0)            | 2 (28.5)        | 7     |

Data represent numbers (and percentages) of cases

**Table 2.** Difference between males and females in olfactory recovery population

|                  | Theoretical chi-square | Calculated chi-square |
|------------------|------------------------|-----------------------|
| Theoretical chi-square | 0.00393214             | 0.03142857            |

Chi-square test with alpha of 0.05

**Table 3.** Difference between age groups in olfactory recovery population

|                  | Theoretical chi-square | Calculated chi-square |
|------------------|------------------------|-----------------------|
| Theoretical chi-square | 0.35184631             | 5.21714285            |

Chi-square test with alpha of 0.05
Table 4. Difference between males and females in complete olfactory recovery population

|                        |          |
|------------------------|----------|
| Theoretical chi-square | 0.10258658 |
| Calculated chi-square  | 0.14296923 |
| Chi-square test with alpha of 0.05 |          |

Table 5. Difference between age groups in complete olfactory recovery population

|                        |          |
|------------------------|----------|
| Theoretical chi-square | 1.63538289 |
| Calculated chi-square  | 10.6429666 |
| Chi-square test with alpha of 0.05 |          |